AlphAIAlphAI — Financial news for AI agents
tradingview.com$IONS

Ionis Pharmaceuticals 3Q 2026: Revenue $242.72M, EPS ($0.66) — 10-Q Summary

Ionis Pharmaceuticals reported 3Q 2026 revenue of $242.72M, up 54.9% YoY, with a net loss of $109.97M, narrowed from $128.61M. Revenue growth was driven by DAWNZERA sales and collaboration payments, while lower R&D expenses reduced losses. The company launched new products and achieved collaboration milestones, but some clinical trials missed primary endpoints.

Original reporting
tradingview.com
Published Nov 9, 2026, 1:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 1:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Ionis Pharmaceuticals 3Q 2026: Revenue $242.72M, EPS ($0.66) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$IONSBullishMed
01

Why it matters

The earnings beat could trigger short covering and buying interest, especially given the narrowing loss and strong product sales.

02

Market read

First‑report earnings data for a mid‑cap biotech; potential catalyst for short‑term price movement.

03

What to watch

Phase 3 trial failures for eplontersen and pelacarsen could weigh on future outlook.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Ionis Pharmaceuticals is a U.S. biotech focused on RNA‑based therapeutics. The 10‑Q filing provides its first detailed Q3 2026 financials.

Company-level read

Ticker impact

$IONSBullishHigh confidence
Context

Ionis Pharmaceuticals reported Q3 2026 revenue of $242.7M, a 55% YoY increase, and narrowed net loss, marking the first public disclosure of these results.

Expected impact

likely upward pressure as the market prices in the revenue beat and loss improvement

Evidence & confidence

The report shows a material revenue jump and loss reduction, which are fresh, material facts for a biotech.

Market effects

Sector

Biotech sector may see modest rally on strong Q3 data from Ionis.

Regional

U.S. biotech investors could adjust exposure to RNA therapeutics.

Global

Limited to investors tracking biotech earnings.

Counterpoint

What could challenge this read

The revenue surge may be unsustainable; upcoming trial failures could offset gains.

Key entities

  • company
    Ionis Pharmaceuticals

    U.S. biotech firm reporting Q3 2026 results.

Read at source← All news

StoryIonis cuts TRYNGOLZA outlook after slower launch despite Q3 revenue growth

Also covered by

5 outlets

Related articles

$IONSHighAI 8/10

Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings

Ionis Pharmaceuticals' stock fell 28.5% post-Q3 2026 earnings despite beating estimates. Investors were disappointed by slower-than-expected Tryngolza sales and reduced full-year guidance to $50M. Wainua royalties also missed estimates. Dawnzera sales grew 40% sequentially. Ionis pushed back positive cash flow target to 2029. Competition from Arrowhead and Alnylam adds to concerns.

tradingview.com
$TEVAHigh

FDA Drug Approvals In October 2026

The FDA approved five drugs in October 2026: Teva's Weltruza (TEVA) for schizophrenia, Asahi Kasei's Hovilpri (3407.T) for herpes, Alcon's Brytly (ALC) for eye redness, GSK and Ionis' Hibsago (GSK, IONS) for hepatitis B, and Xbrane and STADA's Lucamzi for retinal diseases. Key details include efficacy, pricing, and competitor landscape.

rttnews.com
$IONSHighAI 8/10

Ionis Pharmaceuticals Inc (IONS) (Q3 2026) Earnings Call Highlights: DAWNZERA Momentum

Ionis Pharmaceuticals (IONS) reduced 2026 revenue guidance to $50M due to slower TRYNGOLZA launch and Phase III setbacks. Cash flow breakeven delayed to 2029. Only 24% of prescribers have written multiple prescriptions. Management cited education needs and payer coverage as key factors. Q3 cash position was $1.9B, with $1.6B expected by year-end. 2027 guidance deferred to February call.

finance.yahoo.com
$IONSHighAI 8/10

Key facts: Ionis Q3 Loss, Mixed Trial Results; HIBSAGO Wins Approvals

Ionis Pharmaceuticals (IONS) reported Q3 2026 revenue of $243M, up 54.8% YoY, and a net loss of $110M. It lowered TRYNGOLZA sales guidance to $50M. Mixed trial results: sefaxersen and ulefnersen showed positive data, while pelacarsen and eplontersen missed Phase 3 goals. HIBSAGO won U.S., Japan, and Canada approvals, triggering a $30M milestone. The average 12-month price target fell to $83.38, with a consensus Buy rating.

tradingview.com